The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases.

IF 2 Q3 RESPIRATORY SYSTEM Pulmonary Medicine Pub Date : 2021-06-18 eCollection Date: 2021-01-01 DOI:10.1155/2021/5488591
Zeeshan Sattar, Alnardo Lora, Bakr Jundi, Christopher Railwah, Patrick Geraghty
{"title":"The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases.","authors":"Zeeshan Sattar,&nbsp;Alnardo Lora,&nbsp;Bakr Jundi,&nbsp;Christopher Railwah,&nbsp;Patrick Geraghty","doi":"10.1155/2021/5488591","DOIUrl":null,"url":null,"abstract":"<p><p>The S100 protein family consists of over 20 members in humans that are involved in many intracellular and extracellular processes, including proliferation, differentiation, apoptosis, Ca<sub>2</sub> <sup>+</sup> homeostasis, energy metabolism, inflammation, tissue repair, and migration/invasion. Although there are structural similarities between each member, they are not functionally interchangeable. The S100 proteins function both as intracellular Ca<sup>2+</sup> sensors and as extracellular factors. Dysregulated responses of multiple members of the S100 family are observed in several diseases, including the lungs (asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and lung cancer). To this degree, extensive research was undertaken to identify their roles in pulmonary disease pathogenesis and the identification of inhibitors for several S100 family members that have progressed to clinical trials in patients for nonpulmonary conditions. This review outlines the potential role of each S100 protein in pulmonary diseases, details the possible mechanisms observed in diseases, and outlines potential therapeutic strategies for treatment.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214497/pdf/","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/5488591","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 14

Abstract

The S100 protein family consists of over 20 members in humans that are involved in many intracellular and extracellular processes, including proliferation, differentiation, apoptosis, Ca2 + homeostasis, energy metabolism, inflammation, tissue repair, and migration/invasion. Although there are structural similarities between each member, they are not functionally interchangeable. The S100 proteins function both as intracellular Ca2+ sensors and as extracellular factors. Dysregulated responses of multiple members of the S100 family are observed in several diseases, including the lungs (asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and lung cancer). To this degree, extensive research was undertaken to identify their roles in pulmonary disease pathogenesis and the identification of inhibitors for several S100 family members that have progressed to clinical trials in patients for nonpulmonary conditions. This review outlines the potential role of each S100 protein in pulmonary diseases, details the possible mechanisms observed in diseases, and outlines potential therapeutic strategies for treatment.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
S100蛋白家族在肺部疾病中的作用及治疗靶点
S100蛋白家族在人类中有超过20个成员,参与许多细胞内和细胞外过程,包括增殖、分化、凋亡、Ca2 +稳态、能量代谢、炎症、组织修复和迁移/入侵。虽然每个成员之间有结构上的相似性,但它们在功能上是不可互换的。S100蛋白既作为细胞内Ca2+传感器又作为细胞外因子。多种S100家族成员的失调反应在多种疾病中被观察到,包括肺(哮喘、慢性阻塞性肺疾病、特发性肺纤维化、囊性纤维化、肺动脉高压和肺癌)。为此,开展了广泛的研究,以确定它们在肺部疾病发病机制中的作用,并确定几种S100家族成员的抑制剂,这些抑制剂已在非肺部疾病患者中进行临床试验。本文概述了每种S100蛋白在肺部疾病中的潜在作用,详细介绍了在疾病中观察到的可能机制,并概述了潜在的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pulmonary Medicine
Pulmonary Medicine RESPIRATORY SYSTEM-
CiteScore
10.20
自引率
0.00%
发文量
4
审稿时长
14 weeks
期刊最新文献
Practice Variations in the Diagnosis and Treatment of Pulmonary Embolism. The Impact of COVID-19 Pandemic on Respiratory Syncytial Virus Infection in Children. Dual-Task Performance in Individuals With Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-Analysis. Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Adherence to the ISHLT Protocol for the Referral of Patients with Idiopathic Pulmonary Fibrosis to the Transplantation Center among of Czech Centers for Interstitial Lung Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1